Enliven Therapeutics, Inc. (ELVN) - Stock Analysis
Last updated: Mar 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High liquidity • No revenue • Persistent cash burn ELVN is a well‑capitalized, virtually debt‑free company with substantial cash/investments (~$462.6M) and high liquidity but no FY2025 revenue, sustained operating losses and negative cash flow that undermine its premium market valuation.
Price Behavior
Key Price Behavior Insights: • Short-term uptrend • 28.0–28.8 support • 30.70 resistance Support Level: $28.00–$28.80 (primary); $26.02 floor Resistance Level: $30.70 Over the last month the stock has trended up (from $26.02 to $29.02, ~11%) but remains capped by resistance at $30.70 with primary support around $28.00–$28.80 and a lower floor at $26.02.
Sentiment & News
Key News Insights: • Investor outreach • Routine reporting • No new milestones Enliven synchronized an investor-focused fireside chat and its Q4/FY2025 earnings release to emphasize transparent, routine investor communications with no new pipeline or partnership disclosures.
AI Summary
Enliven has shifted from a binary early‑stage risk to a well‑capitalized, event‑driven growth story where ELVN‑001's upcoming Phase‑3 path (and 2026 catalysts) now drive valuation rather than solvency concerns. Monitor for a clearly funded Phase‑3 start, any partnership/commercialization commitments, and signs of burn‑rate acceleration or delayed timelines—each will be the immediate trigger for significant upside or sharp downside.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Active | +0.0% |